Selpercatinib is a first-in-class, highly selective and potent, central nervous system-active
RET kinase inhibitor. In the phase I/II trial, selpercatinib demonstrated clinically meaningful …

Thyroid cancers (TCs) are the most common tumors of the endocrine system and a constant
rise in the number of TC cases has been observed for the past few decades. TCs are one of …

Simple Summary According to the American Cancer Society, approximately 53,000 new
cases of thyroid cancer were diagnosed and more than 2200 people died from the disease …

Background Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor originating from
parafollicular C-cells. It represents 2% of all thyroid malignancies and 0.4-1.4% of all thyroid …

Patients with thyroid cancer (TC) usually have an excellent prognosis; however, 5–10% of
them develop an advanced disease. The prognosis of this subgroup is still favourable if the …

Simple Summary Surgery is generally the treatment of choice for locoregional recurrences of
well-differentiated thyroid carcinomas, but other therapies can be considered on an …

Papillary thyroid carcinoma (PTC) diagnosed at a pediatric age (≤ 18 years), compared with
its adult presentation, is associated with larger primary tumors, more extrathyroidal …

The vast majority of thyroid cancers originate from follicular cells. We outline outstanding
issues at each step along the path of cancer patient care, from prevention to post-treatment …

Thyroid cancer is the most common endocrine cancer. Neurotrophic tyrosine receptor kinase
(NTRK) fusions are oncogenic drivers in multiple solid tumors, including thyroid cancer …

Thyroid cancer is the most common endocrine malignancy, accounting for about 3% of all
cancer cases each year worldwide with increasing incidence, but with the mortality …